Revelation Biosciences, Inc. · NASDAQ:REVB
Revelation Biosciences — Investor Presentation (June 2025)
8 slides from Revelation Biosciences's investor presentation, Jun 25, 2025
Slide 1: Rebalancing inflammation to optimize health
BIOSCIENCES > REVELATION Q\ Rebalancing inflammation to optimize health NASDAQ: REVB www.revbiosciences.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward- looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the
Slide 3: Gemini Platform
Gemini™ Platform The Gemini! platform is based on the AP] PHAD® sss) ; Program Therapeutic Indication Discovery Phase 1 Phase 2 Phase 3 GEM-AKI Acute Kidney Injury — +4 GEM-CKD Chronic Kidney Diese 9§_ JD GEM-PSI Post Surgical Infection TD GEM-PBI Post Burn Infection i <=Zz Portfolio Multiple? as Ge
Slide 4: Gemini Has Large Market Potential
Gemini Has Large Market Potential AKI $6 Billion 5M total patients CKD $9.25 Billion 37M total patients $19+ Billion PSI $3.125 Billion 6.25M total patients PBI $0.75 Billion 30k total patients 2 REVELATION BIOSCIENCES
Slide 5: How Gemini Works
How Gemini Works Reduced Preconditioned inflammation Recovery Gemini No Gemini No Recovery __ > to Longer Recovery Normal State Significant inflammation 2 REVELATION / BIOSCIENCES
Slide 6: Immune Stimulation in Healthy Humans Agree with Cytokines in Healthy Animals
Immune Stimulation in Healthy Humans Agree with Cytokines in Healthy Animals Cytokine Upregulation in Humans (Phase 1 study data in healthy volunteers) IL1-RA IL10 Neutrophil 140000, am bg = L im 3 ae) E 4 20000 7 . 40000 “ I ¢ * 0 s T 40000 — 7 ‘ 20000 [= : ~ : i 7+ a = Placebo Low Dose »Mid dose °
Slide 7: PRIME Phase 1b Clinical Study in CKD Patients Ongoing
PRIME Phase 1b Clinical Study in CKD Patients Ongoing PRIME — PRotective IMmunostimulatory Evaluation A Phase 1b, Randomized, Placebo Controlled, Single Blind, Single-Ascending Dose in Stage 3 and Stage 4 CKD Patients Design + Single dose, dose escalation + 5cohorts, 8 subjects per cohort 1:4 placeb
Slide 8: Thank You!
Thank You! For more information, please visit www.revbiosciences.com 2 REVELATION / \, BIOSCIENCES \/ \
Revelation Biosciences — Investor Presentation (June 2025) on 6ix